- Home
- BIAF vs TXMD Comparison
BIAF vs TXMD Comparison
Compare BIAF & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- TXMD
- Stock Information
- Founded
- BIAF 2014
- TXMD 2008
- Country
- BIAF United States
- TXMD United States
- Employees
- BIAF N/A
- TXMD N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- TXMD Health Care
- Exchange
- BIAF Nasdaq
- TXMD Nasdaq
- Market Cap
- BIAF 12.2M
- TXMD 12.7M
- IPO Year
- BIAF 2022
- TXMD N/A
- Fundamental
- Price
- BIAF $0.23
- TXMD $1.17
- Analyst Decision
- BIAF Hold
- TXMD
- Analyst Count
- BIAF 1
- TXMD 0
- Target Price
- BIAF N/A
- TXMD N/A
- AVG Volume (30 Days)
- BIAF 706.3K
- TXMD 24.2K
- Earning Date
- BIAF 08-14-2025
- TXMD 08-12-2025
- Dividend Yield
- BIAF N/A
- TXMD N/A
- EPS Growth
- BIAF N/A
- TXMD N/A
- EPS
- BIAF N/A
- TXMD N/A
- Revenue
- BIAF $7,681,059.00
- TXMD $2,559,000.00
- Revenue This Year
- BIAF N/A
- TXMD $427.09
- Revenue Next Year
- BIAF $20.00
- TXMD N/A
- P/E Ratio
- BIAF N/A
- TXMD N/A
- Revenue Growth
- BIAF 4.99
- TXMD 156.93
- 52 Week Low
- BIAF $0.16
- TXMD $0.70
- 52 Week High
- BIAF $2.26
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- BIAF 32.85
- TXMD 54.93
- Support Level
- BIAF $0.27
- TXMD $1.06
- Resistance Level
- BIAF $0.30
- TXMD $1.12
- Average True Range (ATR)
- BIAF 0.02
- TXMD 0.04
- MACD
- BIAF -0.01
- TXMD 0.01
- Stochastic Oscillator
- BIAF 2.58
- TXMD 73.27
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.